Search sermorelin side effects and you get a tidy list: flushing, headache, redness where the needle went. That list did not come from a trial. It came from the package insert of a product that left the US market in 2008.
Sermorelin's side effect list comes from a withdrawn drug label. That product, Geref, left the market in 2008. No modern trial has counted harms in healthy adults. The longest controlled dosing ran 16 weeks. There have been 0 randomized trials since 2020. Cancer and blood sugar risk are untracked, not cleared.
What the sermorelin safety record actually contains
It contains three small controlled studies from the 1990s, one clinical commentary, and 11 years on the US market as Geref, from 1997 to 2008. That is close to all of it.
None of those studies was built to count harms. They were endocrine studies. They measured hormones.
| Study | Who | What it measured |
|---|---|---|
| Corpas et al., JCEM, 1992 | Older men | GH and IGF-1 response to GHRH(1-29) twice daily |
| Kerkhofs et al., Am J Physiol, 1993 | Normal men | Sleep architecture |
| Khorram et al., JCEM, 1997 | Age-advanced men and women | Endocrine and metabolic effects over 16 weeks |
The Khorram study is the longest controlled dosing period in the sermorelin literature at 16 weeks. That is the outer edge of what anyone has watched under a protocol.
Since 2020 there have been 0 randomized controlled trials of sermorelin in adults. The safety record is not being added to.
Modern controlled data on a GHRH analog does exist. It is for tesamorelin, a different molecule, studied in people with HIV and abdominal obesity by Russo and colleagues in AIDS in 2024 and by Ellis and colleagues in the Journal of Infectious Diseases in 2025. Useful, but it is not sermorelin and it is not a healthy adult population. The sermorelin complete guide sets out the full development history.
What are the reported side effects of sermorelin?
The commonly repeated list is: pain, redness or swelling at the injection site, flushing, headache, dizziness, nausea, drowsiness, hyperactivity, and a strange taste or trouble swallowing.
That list is real in the sense that somebody wrote it down. It is the adverse reaction section of the Geref labeling. Geref has not been marketed in the US since 2008, so no one has updated it in over fifteen years.
- No frequency you can check. None of the published sermorelin studies in our reference list reports how often any of these happened.
- No adult surveillance system. With no approved product, there is no postmarket reporting stream collecting events.
- Injection-site reaction is the shared one. Every subcutaneous peptide produces it in someone, and it says nothing specific about sermorelin.
- Absence of reports is not absence of risk. Small, short studies cannot detect uncommon harms.
A 2026 Sports Medicine review by Mendias and Awan sorted peptide therapies into approved and unapproved columns for safety and efficacy. Growth hormone secretagogues sit in the unapproved column, and the reason is the size of the evidence, not a finding against them.
The argument that sermorelin is safer than growth hormone
This is the claim that sells it, and it is a mechanistic argument, not a measured one.
Sermorelin is 29 amino acids copying the working end of natural GHRH. It does not replace growth hormone. It asks the pituitary to release its own, in pulses, and the body's somatostatin brake stays connected. In theory you cannot push GH past a physiological ceiling the way an injection of GH can.
Sermorelin: A better approach to management of adult-onset growth hormone insufficiency?
Walker, Clinical Interventions in Aging, 2006 — the paper's title, and it ends in a question markSinha and colleagues make a version of the same case in Translational Andrology and Urology in 2020, reviewing secretagogues for body composition in hypogonadal men. Preserved pulsatility and intact feedback are the selling points.
The measured support for that argument is the IGF-1 curve. In the 1990s studies, GHRH(1-29) brought IGF-1 back into the young-adult range within 14 days, roughly a one-third rise, and nightly dosing held it there through 16 weeks. It went up and it stopped. That is the whole safety story, and it is a hormone level, not a harm count. The before-and-after page breaks those numbers down.
Sermorelin
The compound discussed here, supplied as a research compound with a certificate of analysis matched to the lot.
Cancer and the GHRH receptor: an open question, not a cleared one
Anything that raises IGF-1 gets asked about cancer. For sermorelin there is no human answer, in either direction. There is no cohort, no registry, no long-term follow-up.
What exists is preclinical work on the receptor, and it points both ways at once.
Growth hormone-releasing hormone antagonists increase radiosensitivity in non-small cell lung cancer cells.
Gesmundo et al., International Journal of Molecular Sciences, 2025Blocking the receptor is an active anticancer strategy in the lab. The related antagonist MIA-602 has also been tested against cardiopulmonary injury in mice, per Condor Capcha and colleagues in PNAS in 2023. That line of work implies GHRH receptor signaling does something in tumor tissue worth switching off.
Then there is this.
A potentially effective drug for patients with recurrent glioma: sermorelin.
Chang et al., Annals of Translational Medicine, 2021An agonist nominated as a cancer candidate and antagonists developed as cancer drugs, in the same receptor family, in the same decade. Read neither as a risk figure and neither as reassurance. The biology is unsettled and nobody has run the human study that would settle it.
Blood sugar, sleep, and the effects that were actually measured
Two effects have real data behind them. Neither is what the marketing leads with.
Sleep. Kerkhofs and colleagues gave GHRH to normal men in 1993 and reported sleep-promoting effects. That is a central nervous system effect, measured in a small study, and it is why nightly timing became conventional. Clinic pages list it as a benefit. It is also, literally, a drug effect on sleep.
Blood sugar. Growth hormone opposes insulin, so glucose is the standing question for anything that raises GH. The one modern mechanistic study on the list runs the other way. Louzada and colleagues, in PNAS in 2023, found the GHRH agonist MR-409 protected beta cells against streptozotocin-induced diabetes in mice and in human islets.
- MR-409 is not sermorelin.
- Mice and isolated islets are not people.
- Streptozotocin diabetes is not type 2 diabetes.
So the honest position on glucose is that a protective signal exists in a preclinical model, a plausible opposite signal exists in physiology, and nobody has resolved it in adults using sermorelin.
The risks that are not side effects
Two of the real hazards here have nothing to do with your endocrine system.
It is banned in sport. The World Anti-Doping Agency lists GHRH analogs on the Prohibited List, in and out of competition. Detection is not theoretical. Memdouh and colleagues reviewed assay advances for synthetic GHRH analogs in Drug Testing and Analysis in 2021, and enantiomer-resolving capillary electrophoresis methods were published by Otin and colleagues in 2023. For a tested athlete the risk is a sanction, and the compound clears the blood long before the sanction risk does.
Supply is unverified by default. No approved sermorelin product exists today, so every vial is compounded or sold for research. Purity, sterility and endotoxin load are whatever the lot actually is. Serum stability work on GHRH-related peptides by González-López and colleagues in 2023 is a reminder that these molecules degrade on a clock; reported serum half-life for sermorelin runs 26 to 38 minutes.
The checkable parts are the ones worth checking: what a certificate of analysis has to show, storage temperature, what the diluent is, and the legal status of research peptides. A mislabeled vial is a side effect risk that no trial can characterize.
Sermorelin
Third-party tested research compounds, each shipped with a batch-matched certificate of analysis showing HPLC purity and mass-spec identity — the documentation this site argues you should hold any supplier to.
What to know now
- The widely copied sermorelin side effect list comes from the Geref label, withdrawn in 2008, not from any published trial.
- The longest controlled dosing period in the literature is 16 weeks, in a small 1997 study of age-advanced men and women.
- There have been 0 randomized controlled trials of sermorelin in adults since 2020, so the record is not growing.
- The safety argument, that intact somatostatin feedback caps GH release, is mechanistic and comes from Walker 2006 and Sinha 2020, not from a harm-endpoint study.
- Cancer and glucose effects are unmeasured in humans; preclinical GHRH receptor work points in both directions at once.
- WADA prohibits GHRH analogs, and published urine assays can detect them.
What we're watching
Watch for a controlled trial of any GHRH analog with adverse events as a stated endpoint. The tesamorelin work in people with HIV, from Russo in 2024 and Ellis in 2025, is the only active line producing modern safety data on this receptor. Nothing comparable is running for sermorelin.
Frequently asked questions
Is sermorelin safe long term?
Nobody knows, because nobody has looked. The longest controlled dosing period in the published literature is 16 weeks. There is no adult cohort, no registry, and no postmarket reporting stream, because no approved product has existed since 2008. Long-term safety here is unstudied, not established.
Does sermorelin cause cancer?
There is no human data on that question for sermorelin, in either direction. Preclinical work is genuinely mixed: Gesmundo and colleagues in 2025 used GHRH antagonists to make lung cancer cells more radiosensitive, while Chang and colleagues in 2021 nominated sermorelin itself as a candidate against recurrent glioma. Neither is a human risk estimate.
Why was Geref taken off the market if sermorelin is safe?
It was discontinued in 2008 for business reasons, not because of a safety finding. That distinction matters, but so does the consequence: withdrawal ended the surveillance that would have accumulated side effect data over the following seventeen years.
Does sermorelin raise blood sugar?
Not answered in people. Growth hormone opposes insulin, which is the reason the question is asked. The one modern mechanistic study on our list, Louzada and colleagues in PNAS in 2023, found the GHRH agonist MR-409 protected beta cells in mice and human islets. That is a different molecule and not a human result.
Is sermorelin safer than HGH injections?
That is the claim, and it rests on mechanism. Sermorelin acts on the pituitary, so the somatostatin brake stays in the loop and GH is released in pulses. Walker in 2006 and Sinha and colleagues in 2020 both make that argument. No study has compared the two with harm as the endpoint.
Will sermorelin show up on a drug test?
For athletes under WADA rules, yes, that is the design goal of current assays. GHRH analogs are on the Prohibited List, and detection methods for synthetic analogs in urine were reviewed by Memdouh and colleagues in 2021. Standard employment drug panels do not test for it.
References
- Walker, R. F. (2006). Sermorelin: A better approach to management of adult-onset growth hormone insufficiency? Clinical Interventions in Aging, 1(4), 307–308. https://doi.org/10.2147/ciia.2006.1.4.307
- Khorram, O., Laughlin, G. A., & Yen, S. S. C. (1997). Endocrine and metabolic effects of long-term administration of [Nle²⁷]growth hormone-releasing hormone-(1-29)-NH₂ in age-advanced men and women. The Journal of Clinical Endocrinology & Metabolism, 82(5), 1472–1479. https://doi.org/10.1210/jcem.82.5.3943
- Corpas, E., Harman, S. M., Piñeyro, M. A., et al. (1992). Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. The Journal of Clinical Endocrinology & Metabolism, 75(2), 530–535. https://doi.org/10.1210/jcem.75.2.1379256
- Kerkhofs, M., Van Cauter, E., Van Onderbergen, A., et al. (1993). Sleep-promoting effects of growth hormone-releasing hormone in normal men. American Journal of Physiology-Endocrinology and Metabolism, 264(4), E594–E598. https://doi.org/10.1152/ajpendo.1993.264.4.e594
- Sinha, D. K., Balasubramanian, A., Tatem, A. J., et al. (2020). Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Translational Andrology and Urology, 9(Suppl 2), S149–S159. https://doi.org/10.21037/tau.2019.11.30
- Louzada, R. A., Blandino-Rosano, M., Flores, S., et al. (2023). GHRH agonist MR-409 protects β-cells from streptozotocin-induced diabetes. Proceedings of the National Academy of Sciences, 120(25), e2209810120. https://doi.org/10.1073/pnas.2209810120
- Gesmundo, I., Pedrolli, F., Giglioli, F. R., et al. (2025). Growth hormone-releasing hormone antagonists increase radiosensitivity in non-small cell lung cancer cells. International Journal of Molecular Sciences, 26(7), 3267. https://doi.org/10.3390/ijms26073267
- Chang, Y., Huang, R., Zhai, Y., et al. (2021). A potentially effective drug for patients with recurrent glioma: sermorelin. Annals of Translational Medicine, 9(5), 406. https://doi.org/10.21037/atm-20-6561
- Condor Capcha, J. M., Kamiar, A., Robleto, E., et al. (2023). Growth hormone-releasing hormone receptor antagonist MIA-602 attenuates cardiopulmonary injury induced by BSL-2 rVSV-SARS-CoV-2 in hACE2 mice. Proceedings of the National Academy of Sciences, 120(48), e2308342120. https://doi.org/10.1073/pnas.2308342120
- Russo, S. C., Ockene, M. W., Arpante, A. K., et al. (2024). Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors. AIDS, 38(12), 1758–1764. https://doi.org/10.1097/QAD.0000000000003965
- Ellis, R. J., Vaida, F., Hu, K., et al. (2025). Effects of tesamorelin on neurocognitive impairment in persons with HIV and abdominal obesity. Journal of Infectious Diseases, 231(5), 1230–1238. https://doi.org/10.1093/infdis/jiaf012
- World Anti-Doping Agency. The Prohibited List 2026. https://www.wada-ama.org/en/prohibited-list
- Memdouh, S., Gavrilović, I., Ng, K., Cowan, D., & Abbate, V. (2021). Advances in the detection of growth hormone releasing hormone synthetic analogs. Drug Testing and Analysis, 13(11–12), 1871–1887. https://doi.org/10.1002/dta.3183
- González-López, N. M., Guerra-Acero-Turizo, L. M., Blanco-Medina, I., et al. (2023). In-house standards derived from doping peptides: Enzymatic and serum stability and degradation profile of GHRP and GHRH-related peptides. Biomedical Chromatography, 37(12), e5741. https://doi.org/10.1002/bmc.5741